Akebia's Third Quarter 2026 Financial Results - AKEBIA THERAPEUTICS INC

Financial Performance:

• Total revenue decreased to $36.9 million in Q3 2026 from $58.8 million in Q3 2025.
• VASIO net product revenue rose 11% to $14.8 million despite a 140% increase in patients (approx. 11,500 on therapy), primarily due to a channel inventory drawdown of $4–5 million driven by lower average dosing (810mg vs. 900mg expected) and reduced dialysis compliance (approx. 10-11 sessions/month vs. expected 12).
• Rixia revenue declined to $20 million from $42.5 million due to generic competition and pricing pressures.
• R&D expenses increased to $16.2 million (up from $14.9 million) driven by Phase II trials for EBRI and PROLI; SG&A decreased to $23.5 million (down from $29.1 million) due to lower marketing and headcount costs, partially offset by a $1.3 million restructuring charge.
• Net loss widened to $14.4 million from a net income of $0.5 million in the prior year period.
• Cash and cash equivalents stood at $159.3 million as of quarter-end, including $6.6 million from ATM proceeds; funds are projected to cover operating needs for at least two years pending refinancing of the senior secured term loan.

Guidance and Future Outlook:

• Management expects continued patient growth in Q4, driven by mid-sized dialysis providers (USRC, IRC, DCI) and a deliberate rollout at DaVita.
• Post-TdapA launch on January 1, 2027, will expand eligibility to nearly all clinically eligible patients, integrating VASIO into the bundled dialysis payment system with pricing estimated between $1,000 and $1,500 annually to remain competitive with ESAs.
• Long-term goal is to achieve 200,000 to 250,000 patients on VASIO, representing potential multi-hundred million dollar peak revenue.
• Anticipates continued decline in Rixia revenues throughout 2026 and 2027 due to generic competition.
• Projects initial clinical data for the EBRI basket trial in rare kidney diseases to be available in 2027.

Business Segments and Product Lines:

• Vasio: Currently treats 20% of anemia patients at three mid-sized dialysis organizations; 25% of discontinued patients have restarted therapy. New VOCAL study data confirms non-inferiority to Epogen (Mercera) for TIW dosing.
• Rare Kidney Disease Pipeline: Phase II trials for Prilisiglot (FSGS) and EBRI (basket trial for C3G, IgA Nephropathy, and Lupus Nephritis) are ongoing; preclinical data supports Prilisiglot efficacy.
• EBRI: A tissue-targeted next-generation complement inhibitor aiming to reduce proteinuria and stabilize kidney function without systemic alternative pathway inhibition (reducing infection risk compared to current market standards).
• VATADUSTAT (Vasio): Data from the VOICE trial showed a 10% reduction in hospitalizations and lower exposure-adjusted serious adverse events (1.2-1.5 vs. 13-14.2 per 100 patient years) compared to ESAs; health economic modeling suggests a $6,200 annual cost savings per patient.

Market and Competitive Landscape:

• Adoption at Large Dialysis Organizations (LDOs) remains a bottleneck; DaVita is negotiating a multi-year extension of its TdapA contract, signaling serious intent to scale, though rollout is expected to be deliberate.
• Fresenius is noted as "compelled" by VOICE data but faces organizational transition (new CMO/CEO), likely delaying adoption relative to DaVita.
• Payors have limited influence as VASIO is now reimbursed within the bundled dialysis payment; utilization decisions rest with dialysis providers and nephrologists.
• Physician-to-physician influence is critical, with estimated 33% overlap between mid-sized and DaVita nephrologists, and over 50% overlap including Fresenius.

Risks and Challenges:

• Pricing Pressure: Market dynamics and competitor (Mercera) price reductions are forcing VASIO pricing down to an estimated $1,000–$1,500 annual cost.
• Operational Hurdles: Lower-than-expected dialysis session attendance and variable physician dosing strategies have created channel inventory imbalances and suppressed quarterly revenue recognition.
• Adoption Speed: Transitioning from mid-sized to large dialysis organizations is historically slow and dependent on complex operational integration and physician habituation.
• Generic Competition: Ongoing erosion of Rixia revenues due to market entry of generic alternatives.

Management Commentary and Tone:

• Tone is cautiously optimistic regarding long-term value, driven by "outcome-based" data (VOICE) that differentiates VASIO from ESAs.
• CEO John Butler acknowledged frustration with the slow adoption at LDOs but expressed confidence that clinical evidence will eventually drive standard-of-care status.
• Acknowledged the resignation of Chief Commercial Officer Nicholas Grund, transitioning him to a consulting role to assist with contract extensions and LDO adoption strategies.
• Management emphasized that while revenue volatility exists due to inventory shifts, underlying patient demand remains strong ($19M–$20M estimated end-user demand in Q3).

Analyst Questions and Answers:

• DaVita Ramp-up: Management confirmed DaVita's request to extend contracts implies a larger planned rollout, though specific ramp numbers remain confidential; the focus is on "deliberate" adoption.
• VOCAL Data: CMO Dr. Stephen Burke highlighted that deeper analyses (hemoglobin stability, transfusion rates, proteomics/metabolomics) are pending to further differentiate VASIO from ESAs.
• Pricing Drivers: The $1,000–$1,500 price range is attributed to lower average doses, reduced compliance, and broader ESA price compression (specifically Mercera).
• Rare Disease Differentiation: EBRI aims to reduce proteinuria without systemic complement inhibition (avoiding "box warnings" for infections associated with current complement inhibitors).

Other Key Points:

• The VOICE trial established non-inferiority and superiority for VASIO vs. ESA regarding a composite hospitalization endpoint (p=0.0016).
• Post-TdapA reimbursement shifts from line-item billing to the bundled dialysis payment, removing prior authorization hurdles for eligibility.
• Management highlighted that 25% of previously discontinued VASIO patients have restarted therapy, indicating renewed interest.
• No specific timing updates were provided for Prilisiglot enrollment due to the competitive FSGS landscape, though enrollment pace is expected to mirror other trials.